Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.

While Roche saw a 1 percent decline in full-year 2024 diagnostics sales year over year, the base business within the division rose 8 percent. Overall, Roche reported ...

For Q1 2025, Danaher said it expects core revenues will decline in the low-single-digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...